{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T18:34:16Z","timestamp":1782930856251,"version":"3.54.5"},"reference-count":115,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,11,26]],"date-time":"2025-11-26T00:00:00Z","timestamp":1764115200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2025,11,26]],"date-time":"2025-11-26T00:00:00Z","timestamp":1764115200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"name":"GSK"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Oncol Ther"],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1007\/s40487-025-00400-z","type":"journal-article","created":{"date-parts":[[2025,11,26]],"date-time":"2025-11-26T11:52:35Z","timestamp":1764157955000},"page":"113-154","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Burden of Treatment, Treatment Sequencing and Healthcare Resource Utilization in Multiple Myeloma in Latin America: A Targeted Literature Review"],"prefix":"10.1007","volume":"14","author":[{"given":"Cristian Maximiliano","family":"Seehaus","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guillermina","family":"Remaggi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jayr Schmidt","family":"Filho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paola","family":"Ochoa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ricardo","family":"Bigni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberto Jos\u00e9 Pessoa","family":"de Magalh\u00e3es","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruddy","family":"Dalfeor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bhumika","family":"Aggarwal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudia","family":"Soares","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacopo","family":"Bitetti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,11,26]]},"reference":[{"issue":"5","key":"400_CR1","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1001\/jama.2022.0003","volume":"327","author":"AJ Cowan","year":"2022","unstructured":"Cowan AJ, Green DJ, Kwok M, Lee S, Coffey DG, Holmberg LA, et al. Diagnosis and management of multiple myeloma: a review. JAMA. 2022;327(5):464\u201377. https:\/\/doi.org\/10.1001\/jama.2022.0003.","journal-title":"JAMA"},{"key":"400_CR2","unstructured":"Global Cancer Observatory: Data visualization tools for exploring the global cancer burden in 2022. https:\/\/gco.iarc.who.int\/today (2024). Accessed Nov 28 2024."},{"issue":"1","key":"400_CR3","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1007\/s40265-017-0841-y","volume":"78","author":"IS Nijhof","year":"2018","unstructured":"Nijhof IS, van de Donk N, Zweegman S, Lokhorst HM. Current and new therapeutic strategies for relapsed and refractory multiple myeloma: an update. Drugs. 2018;78(1):19\u201337. https:\/\/doi.org\/10.1007\/s40265-017-0841-y.","journal-title":"Drugs"},{"issue":"3","key":"400_CR4","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1016\/j.annonc.2020.11.014","volume":"32","author":"MA Dimopoulos","year":"2021","unstructured":"Dimopoulos MA, Moreau P, Terpos E, Mateos MV, Zweegman S, Cook G, et al. Multiple myeloma: EHA-ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2021;32(3):309\u201322. https:\/\/doi.org\/10.1016\/j.annonc.2020.11.014.","journal-title":"Ann Oncol"},{"key":"400_CR5","doi-asserted-by":"publisher","unstructured":"Moreau P, San Miguel J, Sonneveld P, Mateos MV, Zamagni E, Avet-Loiseau H, et al. Multiple myeloma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2017;28(Suppl 4):iv52\u201361. https:\/\/doi.org\/10.1093\/annonc\/mdx096.","DOI":"10.1093\/annonc\/mdx096"},{"issue":"4","key":"400_CR6","doi-asserted-by":"publisher","first-page":"867","DOI":"10.1002\/jha2.905","volume":"5","author":"VT de Moraes Hungria","year":"2024","unstructured":"de Moraes Hungria VT, Pe\u00f1a C, G\u00f3mez-Almaguer D, Mart\u00ednez-Cordero H, Sch\u00fctz NP, Blunk V. Multiple myeloma in Latin America: a systematic review. eJHaem. 2024;5(4):867\u201378. https:\/\/doi.org\/10.1002\/jha2.905.","journal-title":"eJHaem"},{"key":"400_CR7","unstructured":"Argentine Agency of the Registry of the National Administration of Medicines FaMTA. INFORMACI\u00d3N PARA EL PACIENTE\u2014Darzalex\u00ae (Daratumumab) 100 mg\/5 ml; 400 mg\/20 ml, Buenos Aires; 2022."},{"key":"400_CR8","unstructured":"Argentine Agency of the Registry of the National Administration of Medicines FaMTA. Revlimid\u00ae5\/10\/15\/25 mg Product Information\u2014Argentina. Buenos Aires; 2023."},{"key":"400_CR9","unstructured":"Ag\u00eancia Nacional de Vigil\u00e2ncia Sanit\u00e1ria\u2014Anvisa: Novo tratamento de c\u00e2ncer \u00e9 aprovado pela Anvisa (2022). https:\/\/www.gov.br\/anvisa\/pt-br\/assuntos\/noticias-anvisa\/2018\/novo-tratamento-de-cancer-e-aprovado-pela-anvisa. Accessed May 2 2025."},{"issue":"6","key":"400_CR10","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1038\/s41408-022-00695-5","volume":"12","author":"S Kumar","year":"2022","unstructured":"Kumar S, Baizer L, Callander NS, Giralt SA, Hillengass J, Freidlin B, et al. Gaps and opportunities in the treatment of relapsed-refractory multiple myeloma: consensus recommendations of the NCI multiple myeloma steering committee. Blood Cancer J. 2022;12(6):98. https:\/\/doi.org\/10.1038\/s41408-022-00695-5.","journal-title":"Blood Cancer J"},{"issue":"2","key":"400_CR11","doi-asserted-by":"publisher","first-page":"2322","DOI":"10.3390\/curroncol30020179","volume":"30","author":"P Bhatt","year":"2023","unstructured":"Bhatt P, Kloock C, Comenzo R. Relapsed\/refractory multiple myeloma: a review of available therapies and clinical scenarios encountered in myeloma relapse. Curr Oncol. 2023;30(2):2322\u201347. https:\/\/doi.org\/10.3390\/curroncol30020179.","journal-title":"Curr Oncol"},{"issue":"8","key":"400_CR12","doi-asserted-by":"publisher","first-page":"590","DOI":"10.1038\/s41571-024-00913-y","volume":"21","author":"P Neri","year":"2024","unstructured":"Neri P, Leblay N, Lee H, Gulla A, Bahlis NJ, Anderson KC. Just scratching the surface: novel treatment approaches for multiple myeloma targeting cell membrane proteins. Nat Rev Clin Oncol. 2024;21(8):590\u2013609. https:\/\/doi.org\/10.1038\/s41571-024-00913-y.","journal-title":"Nat Rev Clin Oncol"},{"key":"400_CR13","doi-asserted-by":"publisher","DOI":"10.1155\/2015\/341430","volume":"2015","author":"WC Yang","year":"2015","unstructured":"Yang WC, Lin SF. Mechanisms of drug resistance in relapse and refractory multiple myeloma. BioMed Res Int. 2015;2015:341430. https:\/\/doi.org\/10.1155\/2015\/341430.","journal-title":"BioMed Res Int"},{"issue":"23","key":"400_CR14","doi-asserted-by":"publisher","first-page":"5993","DOI":"10.1182\/bloodadvances.2024014139","volume":"8","author":"MS Ebraheem","year":"2024","unstructured":"Ebraheem MS, Chakraborty R, Rochwerg B, Visram A, Mohyuddin GR, Venner CP, et al. Quadruplet regimens for patients with newly diagnosed multiple myeloma: a systematic review and meta-analysis. Blood Adv. 2024;8(23):5993\u20136002. https:\/\/doi.org\/10.1182\/bloodadvances.2024014139.","journal-title":"Blood Adv"},{"issue":"9","key":"400_CR15","doi-asserted-by":"publisher","first-page":"1802","DOI":"10.1002\/ajh.27422","volume":"99","author":"SV Rajkumar","year":"2024","unstructured":"Rajkumar SV. Multiple myeloma: 2024 update on diagnosis, risk-stratification, and management. Am J Hematol. 2024;99(9):1802\u201324. https:\/\/doi.org\/10.1002\/ajh.27422.","journal-title":"Am J Hematol"},{"issue":"Suppl 1","key":"400_CR16","doi-asserted-by":"publisher","first-page":"S100","DOI":"10.1016\/S2152-2650(24)00363-X","volume":"24","author":"V Hungria","year":"2024","unstructured":"Hungria V. MM therapy in resource-constrained including maintenance. Clin Lymphoma Myeloma Leuk. 2024;24(Suppl 1):S100\u20131. https:\/\/doi.org\/10.1016\/S2152-2650(24)00363-X.","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"3","key":"400_CR17","doi-asserted-by":"publisher","first-page":"780","DOI":"10.1111\/bjh.19627","volume":"205","author":"MA Hartley-Brown","year":"2024","unstructured":"Hartley-Brown MA, Weisel K, Bitetti J, Carter JA, McNamara S, Purser M, et al. Multiple myeloma refractory to lenalidomide: a systematic literature review of trials and real-world evidence. Br J Haematol. 2024;205(3):780\u201397.","journal-title":"Br J Haematol"},{"issue":"Suppl 1","key":"400_CR18","doi-asserted-by":"publisher","first-page":"7324","DOI":"10.1182\/blood-2022-165792","volume":"140","author":"E Kastritis","year":"2022","unstructured":"Kastritis E, Theodorakakou F, Ntanasis-Stathopoulos I, Spiliopoulou V, Solia E, Malandrakis P, et al. Management and outcomes of anti-CD38 refractory myeloma patients: the impact of retreatment and of subsequent therapies. Blood. 2022;140(Suppl 1):7324\u20135. https:\/\/doi.org\/10.1182\/blood-2022-165792.","journal-title":"Blood"},{"issue":"Suppl 6","key":"400_CR19","doi-asserted-by":"publisher","first-page":"S31","DOI":"10.1016\/j.jval.2024.03.163","volume":"27","author":"SC,J McNamara","year":"2024","unstructured":"McNamara SC J, Pandey A, Bitetti J, Boytsov N, Purser M, Iheanacho I. CO75 clinical outcomes associated with anti-CD38 retreatment in relapsed\/refractory multiple myeloma: a review of the literature. Value Health. 2024;27(Suppl 6):S31. https:\/\/doi.org\/10.1016\/j.jval.2024.03.163.","journal-title":"Value Health"},{"key":"400_CR20","unstructured":"da Silva Ferreira K, Rafael Maciel JF, de Souza Rego Pinto Carvalho DP, Campos de Azevedo I, Fortes Vitor A, Ferreira J\u00fanior MA. Caracterizaci\u00f3n cl\u00ednica y supervivencia de pacientes con m\u00faltiple mieloma en un estado del noreste Brasil. Rev Cuba Hematol Inmunol Hemoter. 2017;33(2):1\u20139."},{"issue":"13","key":"400_CR21","doi-asserted-by":"publisher","first-page":"3112","DOI":"10.1080\/10428194.2020.1804558","volume":"61","author":"C Pe\u00f1a","year":"2020","unstructured":"Pe\u00f1a C, Riva E, Schutz N, Tar\u00edn-Arzaga L, Mart\u00ednez-Cordero H, Bove V, et al. Different outcomes for transplant-eligible newly diagnosed multiple myeloma patients in Latin America according to the public versus private management: a GELAMM study. Leuk Lymphoma. 2020;61(13):3112\u20139. https:\/\/doi.org\/10.1080\/10428194.2020.1804558.","journal-title":"Leuk Lymphoma"},{"issue":"3","key":"400_CR22","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1111\/bjh.16124","volume":"188","author":"VT de Moraes Hungria","year":"2020","unstructured":"de Moraes Hungria VT, Mart\u00ednez-Ba\u00f1os DM, Pe\u00f1afiel CR, Miguel CE, Vela-Ojeda J, Remaggi G, et al. Multiple myeloma treatment patterns and clinical outcomes in the Latin America Haemato-Oncology (HOLA) observational study, 2008\u20132016. Br J Haematol. 2020;188(3):383\u201393. https:\/\/doi.org\/10.1111\/bjh.16124.","journal-title":"Br J Haematol"},{"key":"400_CR23","unstructured":"The Economist Group: Multiple myeloma in Latin America: supporting early and equitable access to care to improve patient outcomes (2023). https:\/\/impact.economist.com\/perspectives\/sites\/default\/files\/ei_janssen_mm_latam_final.pdf. Accessed Nov 24 2024."},{"issue":"22","key":"400_CR24","doi-asserted-by":"publisher","first-page":"1549","DOI":"10.2217\/fon-2023-0020","volume":"19","author":"A Ribbands","year":"2023","unstructured":"Ribbands A, Boytsov N, Bailey A, Gorsh B, Luke E, Lambert A. Drivers of physician decision-making and patient perspectives across lines of therapy in multiple myeloma in the USA. Future Oncol. 2023;19(22):1549\u201362.","journal-title":"Future Oncol"},{"key":"400_CR25","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2023.1271657","volume":"10","author":"C Thomas","year":"2023","unstructured":"Thomas C, Ailawadhi S, Popat R, Kleinman D, Ross MM, Gorsh B, et al. Treatment preferences of patients with relapsed or refractory multiple myeloma in the United States, United Kingdom, Italy, Germany, France, and Spain: results from a discrete choice experiment. Front Med. 2023;10:1271657. https:\/\/doi.org\/10.3389\/fmed.2023.1271657.","journal-title":"Front Med"},{"issue":"Suppl 1","key":"400_CR26","doi-asserted-by":"publisher","first-page":"S8","DOI":"10.1002\/ajh.26005","volume":"95","author":"M Choon-Quinones","year":"2020","unstructured":"Choon-Quinones M, Zelei T, Barnett M, Keown P, Durie B, Kalo Z, et al. Exploring the true cost of multiple myeloma. Am J Hematol. 2020;95(Suppl 1):S8\u20139. https:\/\/doi.org\/10.1002\/ajh.26005.","journal-title":"Am J Hematol"},{"issue":"31","key":"400_CR27","doi-asserted-by":"publisher","first-page":"2103","DOI":"10.2217\/fon-2023-0021","volume":"19","author":"J Mart\u00ednez-Lopez","year":"2023","unstructured":"Mart\u00ednez-Lopez J, Bailey A, Lambert A, Luke E, Ribbands A, Erler-Yates N, et al. Real-world treatment patterns, healthcare resource use and disease burden in patients with multiple myeloma in Europe. Future Oncol. 2023;19(31):2103\u201321. https:\/\/doi.org\/10.2217\/fon-2023-0021.","journal-title":"Future Oncol"},{"issue":"1","key":"400_CR28","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1080\/13696998.2020.1867469","volume":"24","author":"TH Steinmetz","year":"2021","unstructured":"Steinmetz TH, Singh M, Lebioda A, Fink L, Schoehl M, Rieth A, et al. Healthcare resource utilization and costs among patients with relapsed and\/or refractory multiple myeloma treated with proteasome inhibitors in real-world clinical practice in Germany. J Med Econ. 2021;24(1):114\u201322. https:\/\/doi.org\/10.1080\/13696998.2020.1867469.","journal-title":"J Med Econ"},{"key":"400_CR29","doi-asserted-by":"publisher","first-page":"3449","DOI":"10.1097\/01.HS9.0000852292.38263.b8","volume":"6","author":"E Crusoe","year":"2022","unstructured":"Crusoe E, Ribeiro G, Zanella K, Perobelli L, Filho JCS, Magalhaes R, et al. Multiple myeloma Brazilian register- how about the transplant eligible patients? HemaSphere. 2022;6:3449\u201350. https:\/\/doi.org\/10.1097\/01.HS9.0000852292.38263.b8.","journal-title":"HemaSphere"},{"issue":"4","key":"400_CR30","doi-asserted-by":"publisher","first-page":"941","DOI":"10.1007\/s00277-019-03602-4","volume":"98","author":"VTM Hungria","year":"2019","unstructured":"Hungria VTM, Lee JH, Maiolino A, de Queiroz Crusoe E, Martinez G, Bittencourt R, et al. Survival differences in multiple myeloma in Latin America and Asia: a comparison involving 3664 patients from regional registries. Ann Hematol. 2019;98(4):941\u20139. https:\/\/doi.org\/10.1007\/s00277-019-03602-4.","journal-title":"Ann Hematol"},{"issue":"4","key":"400_CR31","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1053\/j.seminhematol.2023.07.001","volume":"60","author":"MJ Mela Osorio","year":"2023","unstructured":"Mela Osorio MJ, Pavlovsky C, Pavlovsky MA. Inequalities in access to treatment in Argentina: differences in management of CLL and multiple myeloma? Semin Hematol. 2023;60(4):209\u201314. https:\/\/doi.org\/10.1053\/j.seminhematol.2023.07.001.","journal-title":"Semin Hematol"},{"issue":"4","key":"400_CR32","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1016\/j.htct.2024.02.024","volume":"46","author":"C Pe\u00f1a","year":"2024","unstructured":"Pe\u00f1a C, Graffigna P, Russo M, Forray E, Bustamante P. Improved overall survival of transplant eligible newly diagnosed multiple myeloma patients in a Chilean public center. How did we achieve it? Hematol Transfus Cell Ther. 2024;46(4):575\u20136. https:\/\/doi.org\/10.1016\/j.htct.2024.02.024.","journal-title":"Hematol Transfus Cell Ther"},{"issue":"3","key":"400_CR33","doi-asserted-by":"publisher","first-page":"331","DOI":"10.4067\/s0034-98872022000300331","volume":"150","author":"F Samaniego","year":"2022","unstructured":"Samaniego F, Bull L, Gonz\u00e1lez N, Araos D, Rojas H, Donoso J, et al. Mieloma m\u00faltiple en Chile. Uso de drogas noveles en dos centros nacionales. Rev Med Chile. 2022;150(3):331\u20138. https:\/\/doi.org\/10.4067\/s0034-98872022000300331.","journal-title":"Rev Med Chile"},{"issue":"5","key":"400_CR34","doi-asserted-by":"publisher","first-page":"2101","DOI":"10.1002\/cam4.1347","volume":"7","author":"MP Curado","year":"2018","unstructured":"Curado MP, Oliveira MM, Silva DRM, Souza DLB. Epidemiology of multiple myeloma in 17 Latin American countries: an update. Cancer Med. 2018;7(5):2101\u20138. https:\/\/doi.org\/10.1002\/cam4.1347.","journal-title":"Cancer Med"},{"key":"400_CR35","doi-asserted-by":"publisher","unstructured":"Guimar\u00e3es Ribeiro A, Ferlay J, Pi\u00f1eros M, Dias de Oliveira Latorre MDR, Tavares Guerreiro Fregnani JH, Bray F. Geographic variations in cancer incidence and mortality in the State of S\u00e3o Paulo, Brazil 2001\u201317. Cancer Epidemiol. 2023;85:102403. https:\/\/doi.org\/10.1016\/j.canep.2023.102403.","DOI":"10.1016\/j.canep.2023.102403"},{"issue":"21","key":"400_CR36","doi-asserted-by":"publisher","first-page":"5704","DOI":"10.1182\/blood.V124.21.5704.5704","volume":"124","author":"M Rizzo","year":"2014","unstructured":"Rizzo M, Xu Y, Iheanacho I, Panjabi S. A systematic literature review on the epidemiological burden in multiple myeloma. Blood. 2014;124(21):5704.","journal-title":"Blood"},{"issue":"9","key":"400_CR37","doi-asserted-by":"publisher","first-page":"A872","DOI":"10.1016\/j.jval.2017.08.2558","volume":"20","author":"M Pineli","year":"2017","unstructured":"Pineli M, Pinho W, Amigo C, Alvarado CA, Figueroa R, Bucheli E. Multiple myeloma: epidemiology and burden of disease analysis in Latin America. Value Health. 2017;20(9):A872. https:\/\/doi.org\/10.1016\/j.jval.2017.08.2558.","journal-title":"Value Health"},{"issue":"2","key":"400_CR38","doi-asserted-by":"publisher","first-page":"99","DOI":"10.29375\/01237047.2306","volume":"17","author":"C Casta\u00f1eda","year":"2014","unstructured":"Casta\u00f1eda C, Pantoja MC, Monta\u00f1o L, Rosselli D. Carfilzomib en el tratamiento de mieloma m\u00faltiple: revisi\u00f3n sistem\u00e1tica de la literatura y experiencia colombiana basada en RIPS. MedUNAB. 2014;17(2):99\u2013106. https:\/\/doi.org\/10.29375\/01237047.2306.","journal-title":"MedUNAB"},{"issue":"Suppl 1","key":"400_CR39","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1182\/blood-2020-139747","volume":"136","author":"V Abello","year":"2020","unstructured":"Abello V, Sossa CL, Idrobo H, Quintero G, Mantilla W, Galvez K, et al. Multiple myeloma multicenter registry in Colombia: the impact of autologous stem transplantation on overall and disease-free survival. Blood. 2020;136(Suppl 1):47\u20138. https:\/\/doi.org\/10.1182\/blood-2020-139747.","journal-title":"Blood"},{"issue":"1","key":"400_CR40","doi-asserted-by":"publisher","first-page":"1","DOI":"10.58814\/01208845.3","volume":"37","author":"JJ Jaramillo-Garc\u00eda","year":"2023","unstructured":"Jaramillo-Garc\u00eda JJ, Orrego-Bustamante D, Barrios-Henao E, Mart\u00ednez-Soto D. Caracterizaci\u00f3n de pacientes con mieloma m\u00faltiple y afectaci\u00f3n de la columna vertebral atendidos en un hospital de tercer nivel de Medell\u00edn. Colombia Rev Colomb Ortop Traumatol. 2023;37(1):1\u201310. https:\/\/doi.org\/10.58814\/01208845.3.","journal-title":"Colombia Rev Colomb Ortop Traumatol"},{"key":"400_CR41","doi-asserted-by":"publisher","unstructured":"Cort\u00e9s MP, Figueroa C, Varela R, Valdivia-Cort\u00e9s K, Barr\u00eda K, Salvo C. Mieloma m\u00faltiple. Experiencia de 9 a\u00f1os en el Hospital Naval Almirante Nef. ARS med (Santiago, En l\u00ednea). 2021;46(2):16\u201324. https:\/\/doi.org\/10.11565\/arsmed.v46i2.1799.","DOI":"10.11565\/arsmed.v46i2.1799"},{"issue":"4","key":"400_CR42","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1590\/1982-0194201800061","volume":"31","author":"MMC Moreira","year":"2018","unstructured":"Moreira MMC, Rodrigues AB, Oliveira PPd, Aguiar MIFd, Cunha GHd, Pinto RMC, et al. Neuropatia perif\u00e9rica em pessoas com mieloma m\u00faltiplo. Acta Paul Enferm. 2018;31(4):439\u201345. https:\/\/doi.org\/10.1590\/1982-0194201800061.","journal-title":"Acta Paul Enferm"},{"key":"400_CR43","doi-asserted-by":"publisher","unstructured":"Carrillo S\u00e1nchez AM, Santiago Esquivel LAD, P\u00e9rez Garc\u00eda CK, Antonio Romero CE, P\u00e9rez Z\u00fa\u00f1iga JM, A\u00f1orve Bailon D. Localizaci\u00f3n de fracturas en el mieloma m\u00faltiple en el Hospital Regional \u201cGral. Ignacio Zaragoza\u201d ISSSTE. Acta m\u00e9dica Grupo \u00c1ngeles. 2021;19(4):497\u2013500. https:\/\/doi.org\/10.35366\/102534.","DOI":"10.35366\/102534"},{"issue":"Suppl 1","key":"400_CR44","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2018-99-114927","volume":"132","author":"V Abello","year":"2018","unstructured":"Abello V, Idrobo H, Sossa CL, Galvez KM, Saavedra D, Solano MH, et al. The status of multiple myeloma in Colombia: first report of the Colombian registry for hemato-oncological diseases (RENEHOC). Asociacion colombiana de hematologia y oncologia (ACHO). Blood. 2018;132(Suppl 1):5597. https:\/\/doi.org\/10.1182\/blood-2018-99-114927.","journal-title":"Blood"},{"issue":"1","key":"400_CR45","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1016\/j.bjhh.2017.09.004","volume":"40","author":"ALMS Dias","year":"2018","unstructured":"Dias ALMS, Higashi F, Peres ALM, Cury P, Cruso\u00e9 EdQ, Hungria VTdM. Multiple myeloma and central nervous system involvement: experience of a Brazilian center. Hematol Transfus Cell Ther. 2018;40(1):30\u20136. https:\/\/doi.org\/10.1016\/j.bjhh.2017.09.004.","journal-title":"Hematol Transfus Cell Ther"},{"key":"400_CR46","doi-asserted-by":"publisher","DOI":"10.1200\/go.23.00182","volume":"9","author":"H Mart\u00ednez-Cordero","year":"2023","unstructured":"Mart\u00ednez-Cordero H, Pe\u00f1a C, Schutz NP, Bove V, Villano F, Beltran C, et al. Patients age 40 years and younger with multiple myeloma have the same prognosis as older patients: an analysis of real-world patients\u2019 evidence from Latin America. JCO Glob Oncol. 2023;9:e2300182. https:\/\/doi.org\/10.1200\/go.23.00182.","journal-title":"JCO Glob Oncol"},{"issue":"Suppl 1","key":"400_CR47","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2023-181336","volume":"142","author":"J Pedraza","year":"2023","unstructured":"Pedraza J, Claudia SM, Cuervo D, Martinez-Cordero H, Quintero HI, Salazar LA, et al. Clinical features and prognostic factors in multiple myeloma patients from Colombia. Real-world data from Renehoc registry. Blood. 2023;142(Suppl 1):6636. https:\/\/doi.org\/10.1182\/blood-2023-181336.","journal-title":"Blood"},{"issue":"4","key":"400_CR48","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1016\/j.htct.2020.07.005","volume":"43","author":"EdQ Cruso\u00e9","year":"2021","unstructured":"Cruso\u00e9 EdQ, Pimenta FCF, Maiolino A, Castro NSd, Pei H, Trufelli D, et al. Results of the daratumumab monotherapy early access treatment protocol in patients from Brazil with relapsed or refractory multiple myeloma. Hematol Transfus Cell Ther. 2021;43(4):417\u201323. https:\/\/doi.org\/10.1016\/j.htct.2020.07.005.","journal-title":"Hematol Transfus Cell Ther"},{"issue":"3","key":"400_CR49","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1080\/17474086.2021.1886073","volume":"14","author":"PJ Duarte","year":"2021","unstructured":"Duarte PJ, Schutz NP, Ochoa P, Yantorno S, Orlando S, Lopresti S, et al. Real-world outcomes for the treatment of relapsed\/refractory multiple myeloma patients with lenalidomide-dexamethasone combinations in a Latin American country. A retrospective cohort study from grupo argentino de mieloma m\u00faltiple. Expert Rev Hematol. 2021;14(3):315\u201322. https:\/\/doi.org\/10.1080\/17474086.2021.1886073.","journal-title":"Expert Rev Hematol"},{"key":"400_CR50","doi-asserted-by":"publisher","first-page":"6654","DOI":"10.1182\/blood-2023-190068","volume":"142","author":"G Quintero","year":"2023","unstructured":"Quintero G, Aruachan S, Figueroa Emiliani J, Galvez K, Salazar LA, Diaz M, et al. Freedo mm: a multicenter observational study of multiple myeloma in second relapse in Colombia. Blood. 2023;142:6654. https:\/\/doi.org\/10.1182\/blood-2023-190068.","journal-title":"Blood"},{"key":"400_CR51","unstructured":"Schutz NP, Duarte P, Shanley C, Cia A, Ochoa P, Corzo A, et al. Argentine multicentric experience of carfilzomib use in relapsed\/refractory multiple myeloma. Report from the GAMM (Grupo Argentino de Mieloma Multiple). Blood. 2017;130(Suppl 1):5439."},{"issue":"3","key":"400_CR52","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1002\/hon.2729","volume":"38","author":"NP Sch\u00fctz","year":"2020","unstructured":"Sch\u00fctz NP, Ochoa P, Duarte P, Remaggi G, Yantorno S, Corzo A, et al. Real world outcomes with bortezomib thalidomide dexamethasone and cyclophosphamide bortezomib dexamethasone induction treatment for transplant eligible multiple myeloma patients in a Latin American country. A retrospective cohort study from Grupo Argentino de Mieloma M\u00faltiple. Hematol Oncol. 2020;38(3):363\u201371. https:\/\/doi.org\/10.1002\/hon.2729.","journal-title":"Hematol Oncol"},{"issue":"3","key":"400_CR53","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1016\/j.clml.2020.11.020","volume":"21","author":"C Vargas-Serafin","year":"2021","unstructured":"Vargas-Serafin C, Acosta-Medina AA, Ordonez-Gonzalez I, Mart\u00ednez-Ba\u00f1os D, Bourlon C. Impact of socioeconomic characteristics and comorbidities on therapy initiation and outcomes of newly diagnosed multiple myeloma: real-world data from a resource-constrained setting. Clin Lymphoma Myeloma Leuk. 2021;21(3):182\u20137. https:\/\/doi.org\/10.1016\/j.clml.2020.11.020.","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"6","key":"400_CR54","doi-asserted-by":"publisher","first-page":"627","DOI":"10.1016\/j.arcmed.2021.02.008","volume":"52","author":"J Vela-Ojeda","year":"2021","unstructured":"Vela-Ojeda J, G\u00f3mez-Almaguer D, Espinoza-Zamora R, Ram\u00edrez-Alvarado AG, Villalobos A, Herrera-Rojas MA, et al. Prescription patterns of daratumumab in patients with multiple myeloma in underprivileged circumstances: a multicenter experience in Mexico. Arch Med Res. 2021;52(6):627\u201334. https:\/\/doi.org\/10.1016\/j.arcmed.2021.02.008.","journal-title":"Arch Med Res"},{"key":"400_CR55","doi-asserted-by":"publisher","DOI":"10.1590\/1414-431x20165128","author":"TBM Castro","year":"2016","unstructured":"Castro TBM, Hallack Neto AE, Atalla A, Ribeiro LC. Pharmacovigilance of patients with multiple myeloma being treated with bortezomib and\/or thalidomide. Braz J Med Biol Res. 2016. https:\/\/doi.org\/10.1590\/1414-431x20165128.","journal-title":"Braz J Med Biol Res"},{"issue":"1","key":"400_CR56","doi-asserted-by":"publisher","first-page":"19","DOI":"10.5581\/1516-8484.20140008","volume":"36","author":"EQ Crusoe","year":"2014","unstructured":"Crusoe EQ, Higashi F, Padilha MPNC, Miranda ECM, Quero AA, Almeida MSS, et al. Outcomes of autologous transplantation for multiple myeloma according to different induction regimens. Rev Bras Hematol Hemoter. 2014;36(1):19\u201324. https:\/\/doi.org\/10.5581\/1516-8484.20140008.","journal-title":"Rev Bras Hematol Hemoter"},{"issue":"1","key":"400_CR57","doi-asserted-by":"publisher","first-page":"e43","DOI":"10.1016\/j.clml.2018.08.005","volume":"19","author":"RJP de Magalh\u00e3es Filho","year":"2019","unstructured":"de Magalh\u00e3es Filho RJP, Crusoe E, Riva E, Bujan W, Conte G, Cabrera JRN, et al. Analysis of availability and access of anti-myeloma drugs and impact on the management of multiple myeloma in Latin American countries. Clin Lymphoma Myeloma Leuk. 2019;19(1):e43\u201350.","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"400_CR58","doi-asserted-by":"publisher","unstructured":"Drummond PLM, Santos R, Reis AMM, Malta JS, Silveira LP, Costa I, Menezes de P\u00e1dua CA. Real-world effectiveness and safety of multiple myeloma treatments based on thalidomide and bortezomib: a retrospective cohort study from 2009 to 2020 in a Brazilian metropolis. Cancer Epidemiol. 2023;85:102377. https:\/\/doi.org\/10.1016\/j.canep.2023.102377.","DOI":"10.1016\/j.canep.2023.102377"},{"issue":"5","key":"400_CR59","volume":"20","author":"HM Lin","year":"2017","unstructured":"Lin HM, Luptakova K, Tanaka PY, Andrade F, Saad R, Clark OA, et al. Real world data on multiple myeloma in Brazil: patterns of care in the private healthcare system. Value Health. 2017;20(5):A124.","journal-title":"Value Health"},{"issue":"12","key":"400_CR60","doi-asserted-by":"publisher","first-page":"1561","DOI":"10.4067\/S0034-98872019001201561","volume":"147","author":"C Pe\u00f1a","year":"2019","unstructured":"Pe\u00f1a C, Rojas-Vallejos J, Espinoza M, Donoso J, Soto P, Cardemil D, et al. Mieloma m\u00faltiple en Chile: Respuesta a tratamiento en pacientes con mieloma m\u00faltiple elegibles para trasplante aut\u00f3logo de progenitores hematopoy\u00e9ticos. Rev Med Chile. 2019;147(12):1561\u20138. https:\/\/doi.org\/10.4067\/S0034-98872019001201561.","journal-title":"Rev Med Chile"},{"key":"400_CR61","doi-asserted-by":"publisher","first-page":"977","DOI":"10.1097\/01.HS9.0000567192.44525.7b","volume":"3","author":"D Rodriguez","year":"2019","unstructured":"Rodriguez D, Ryser R, Ryser J, Gutierrez V, Lopez MJ, Ryser F, et al. Multiple myeloma in patients under 65 years: an analysis of 56 cases from Sanatorio del Salvador in Cordoba. Argentina HemaSphere. 2019;3:977\u20138.","journal-title":"Argentina HemaSphere"},{"issue":"4","key":"400_CR62","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1016\/j.bjhh.2017.05.010","volume":"39","author":"LSVd Silva","year":"2017","unstructured":"Silva LSVd, Crusoe EdQ, Souza LRGd, Chiattone CS, Hungria VTdM. For survival, the emergence of oligoclonal bands after multiple myeloma treatment is less important than achieving complete remission. Rev Bras Hematol Hemoter. 2017;39(4):331\u20136. https:\/\/doi.org\/10.1016\/j.bjhh.2017.05.010.","journal-title":"Rev Bras Hematol Hemoter"},{"issue":"5","key":"400_CR63","doi-asserted-by":"publisher","first-page":"1025","DOI":"10.1007\/s00277-020-03983-x","volume":"99","author":"E Riva","year":"2020","unstructured":"Riva E, Sch\u00fctz N, Pe\u00f1a C, Ruiz-Arg\u00fcelles G, Hopkins CR, Bove V, et al. Significant differences in access to tests and treatments for multiple myeloma between public and private systems in Latin America. Results of a Latin American survey. GELAMM (Grupo de Estudio Latino Americano de Mieloma M\u00faltiple). Ann Hematol. 2020;99(5):1025\u201330. https:\/\/doi.org\/10.1007\/s00277-020-03983-x.","journal-title":"Ann Hematol"},{"key":"400_CR64","doi-asserted-by":"publisher","unstructured":"Kerbauy LN, Parmar S, Kutner JM, de Gusm\u00e3o BM, Hamerschlak N. Hematological approaches to multiple myeloma: trends from a Brazilian subset of hematologists. A cross-sectional study. Sao Paulo Med J. 2016;134(4):335\u201341. https:\/\/doi.org\/10.1590\/1516-3180.2015.0223030416.","DOI":"10.1590\/1516-3180.2015.0223030416"},{"issue":"7","key":"400_CR65","doi-asserted-by":"publisher","first-page":"869","DOI":"10.4067\/s0034-98872018000700869","volume":"146","author":"C Pe\u00f1a","year":"2018","unstructured":"Pe\u00f1a C, Rojas C, Rojas H, Soto P, Cardemil D, Aranda S, et al. Mieloma m\u00faltiple en Chile: pasado, presente y futuro del programa nacional de drogas antineopl\u00e1sicas (PANDA). Revisi\u00f3n de 1.103 pacientes. Rev Med Chile. 2018;146(7):869\u201375. https:\/\/doi.org\/10.4067\/s0034-98872018000700869.","journal-title":"Rev Med Chile"},{"issue":"9","key":"400_CR66","doi-asserted-by":"publisher","first-page":"1946","DOI":"10.1002\/cncr.31305","volume":"124","author":"L Tar\u00edn-Arzaga","year":"2018","unstructured":"Tar\u00edn-Arzaga L, Arredondo-Campos D, Mart\u00ednez-Pacheco V, Mart\u00ednez-Gonz\u00e1lez O, Ram\u00edrez-L\u00f3pez A, G\u00f3mez-De Le\u00f3n A, et al. Impact of the affordability of novel agents in patients with multiple myeloma: real-world data of current clinical practice in Mexico. Cancer. 2018;124(9):1946\u201353. https:\/\/doi.org\/10.1002\/cncr.31305.","journal-title":"Cancer"},{"issue":"4","key":"400_CR67","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1016\/j.rccan.2018.10.001","volume":"22","author":"F Jaramillo","year":"2018","unstructured":"Jaramillo F, Useche E, Garc\u00eda J, Rosales M, Manzi E, Estacio M, et al. Trasplante aut\u00f3logo de c\u00e9lulas madre hematopoy\u00e9ticas en pacientes con diagn\u00f3stico de mieloma m\u00faltiple, experiencia en 9 a\u00f1os. Rev Colomb Cancerol. 2018;22(4):138\u201342. https:\/\/doi.org\/10.1016\/j.rccan.2018.10.001.","journal-title":"Rev Colomb Cancerol"},{"issue":"12","key":"400_CR68","doi-asserted-by":"publisher","first-page":"1497","DOI":"10.4067\/S0034-98872014001200001","volume":"142","author":"M Sarmiento","year":"2014","unstructured":"Sarmiento M, Lira P, Ocqueteau M, Rodr\u00edguez MA, Garc\u00eda MJ, Jara V, et al. Experiencia de 22 a\u00f1os de trasplante aut\u00f3logo de c\u00e9lulas hematopoy\u00e9ticas en pacientes con mieloma m\u00faltiple o amiloidosis sist\u00e9mica. 1992\u20132014. Rev Med Chile. 2014;142(12):1497\u2013501.","journal-title":"Rev Med Chile"},{"issue":"1","key":"400_CR69","doi-asserted-by":"publisher","DOI":"10.1590\/0034-7167-2023-0100","volume":"77","author":"LA Lorca","year":"2024","unstructured":"Lorca LA, Sacomori C, Pe\u00f1a C, Barrera C, Salazar M, Le\u00e3o I, et al. Psychometric properties of the Chilean version of the quality of life questionnaire for multiple myeloma. Rev Bras Enferm. 2024;77(1):e20230100. https:\/\/doi.org\/10.1590\/0034-7167-2023-0100.","journal-title":"Rev Bras Enferm"},{"key":"400_CR70","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1186\/s12913-015-1123-6","volume":"15","author":"IC Saccilotto","year":"2015","unstructured":"Saccilotto IC, Bittencourt RI, Fischer CC, Quevedo A, Hirakata VN, Picon PD. Efficacy of a referral center for patient-centered care in multiple myeloma: a cohort study. BMC Health Serv Res. 2015;15:455. https:\/\/doi.org\/10.1186\/s12913-015-1123-6.","journal-title":"BMC Health Serv Res"},{"issue":"1","key":"400_CR71","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1590\/S1808-185120141301RC105","volume":"13","author":"OJ Bohsain","year":"2014","unstructured":"Bohsain OJ. Quality of life in patients with multiple myeloma treated with percutaneous vertebroplasty. Coluna\/Columna. 2014;13(1):53\u20136. https:\/\/doi.org\/10.1590\/S1808-185120141301RC105.","journal-title":"Coluna\/Columna"},{"issue":"1","key":"400_CR72","doi-asserted-by":"publisher","first-page":"9","DOI":"10.21115\/JBES.v10.n1.p9-14","volume":"10","author":"C Pepe","year":"2018","unstructured":"Pepe C, Asano E, Senna T, Asano E, Rosim RP. Impacto econ\u00f4mico do mieloma m\u00faltiplo no sistema privado de sa\u00fade do Brasil. J Bras Econ Saude. 2018;10(1):9\u201314. https:\/\/doi.org\/10.21115\/JBES.v10.n1.p9-14.","journal-title":"J Bras Econ Saude"},{"issue":"1","key":"400_CR73","doi-asserted-by":"publisher","first-page":"16","DOI":"10.21115\/JBES.v12.n1.p16-22","volume":"12","author":"S Tanaka","year":"2020","unstructured":"Tanaka S, Suri G, Arancibia A, Nascimento D, Magliano C, Aratangy G. Impacto econ\u00f4mico da ado\u00e7\u00e3o de denosumabe em pacientes com met\u00e1stases \u00f3sseas ou mieloma m\u00faltiplo sob a perspectiva do sistema de sa\u00fade privado brasileiro. J Bras Econ Saude. 2020;12(1):16\u201322. https:\/\/doi.org\/10.21115\/JBES.v12.n1.p16-22.","journal-title":"J Bras Econ Saude"},{"key":"400_CR74","doi-asserted-by":"publisher","first-page":"S290","DOI":"10.1016\/j.jval.2018.09.1731","volume":"21","author":"M P\u00e9rez","year":"2018","unstructured":"P\u00e9rez M, Jamotte A, Amaya J, Linares F. Budget impact of denosumab in the prevention of skeletal-related events in patients with multiple myeloma in Colombia. Value Health. 2018;21:S290. https:\/\/doi.org\/10.1016\/j.jval.2018.09.1731.","journal-title":"Value Health"},{"issue":"3","key":"400_CR75","doi-asserted-by":"publisher","first-page":"189","DOI":"10.21115\/JBES.v12.n3.p189-94","volume":"12","author":"S Tanaka","year":"2020","unstructured":"Tanaka S, Maroun R, Martinez C, Nascimento D, Aratangy G. An\u00e1lise de custo por desfecho das novas terapias de combina\u00e7\u00e3o tripla com lenalidomida para o mieloma m\u00faltiplo recidivado\/refrat\u00e1rio no Brasil. J Bras Econ Saude. 2020;12(3):189\u201394. https:\/\/doi.org\/10.21115\/JBES.v12.n3.p189-94.","journal-title":"J Bras Econ Saude"},{"key":"400_CR76","doi-asserted-by":"publisher","first-page":"S446","DOI":"10.1016\/j.jval.2018.09.2639","volume":"21","author":"S Tanaka","year":"2018","unstructured":"Tanaka S, Maroun R, Majer IM, Lemos M, Arancibia A, Ferreira KA, et al. Cost by outcomes analysis of novel triple-combination therapies for relapsed\/refractory multiple myeloma in Brazil. Value Health. 2018;21:S446. https:\/\/doi.org\/10.1016\/j.jval.2018.09.2639.","journal-title":"Value Health"},{"issue":"1","key":"400_CR77","doi-asserted-by":"publisher","first-page":"901","DOI":"10.1186\/s12885-022-09980-9","volume":"22","author":"R Medhekar","year":"2022","unstructured":"Medhekar R, Ran T, Fu AZ, Patel S, Kaila S. Real-world patient characteristics and treatment outcomes among nontransplanted multiple myeloma patients who received bortezomib in combination with lenalidomide and dexamethasone as first line of therapy in the United States. BMC Cancer. 2022;22(1):901. https:\/\/doi.org\/10.1186\/s12885-022-09980-9.","journal-title":"BMC Cancer"},{"issue":"4","key":"400_CR78","doi-asserted-by":"publisher","first-page":"e241","DOI":"10.1016\/j.clml.2021.10.001","volume":"22","author":"EM Ocio","year":"2022","unstructured":"Ocio EM, Montes-Gais\u00e1n C, Bustamante G, Garz\u00f3n S, Gonz\u00e1lez E, P\u00e9rez E, et al. Clinical and sociodemographic characteristics of patients with relapsed and\/or refractory multiple myeloma and their influence on treatment in the real-world setting in Spain: the CharisMMa study. Clin Lymphoma Myeloma Leuk. 2022;22(4):e241\u20139. https:\/\/doi.org\/10.1016\/j.clml.2021.10.001.","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"1","key":"400_CR79","doi-asserted-by":"publisher","first-page":"928","DOI":"10.1080\/16078454.2022.2112643","volume":"27","author":"D G\u00f3mez-Almaguer","year":"2022","unstructured":"G\u00f3mez-Almaguer D, de Moraes Hungria VT. Multiple myeloma in Latin America. Hematology. 2022;27(1):928\u201331. https:\/\/doi.org\/10.1080\/16078454.2022.2112643.","journal-title":"Hematology"},{"key":"400_CR80","doi-asserted-by":"publisher","first-page":"S1","DOI":"10.24875\/GMM.M20000393","volume":"156","author":"JA de la Pe\u00f1a-Celaya","year":"2020","unstructured":"de la Pe\u00f1a-Celaya JA, Aguilar-Luevano J, Alcivar-Cede\u00f1o LM, \u00c1lvarez-Vera JL, Anaya-Cuellar I, A\u00f1orve-Hern\u00e1ndez E, et al. Mexican consensus of multiple myeloma. Gac Med Mex. 2020;156:S1\u201349. https:\/\/doi.org\/10.24875\/GMM.M20000393.","journal-title":"Gac Med Mex"},{"key":"400_CR81","doi-asserted-by":"publisher","unstructured":"Maiolino A, Cruso\u00e9 EdQ, Martinez GA, Braga WMT, Farias DLCd, Bittencourt RI, et al. Guidelines on the diagnosis and management of multiple myeloma treatment: Associac ao Brasileira de Hematologia e Hemoterapia e Terapia Celular Project guidelines: Associa\u00e7\u00e3o M\u00e9dica Brasileira\u20142022. Part I. Hematol Transfus Cell Ther. 2022;44(3):410\u20138. https:\/\/doi.org\/10.1016\/j.htct.2022.06.003.","DOI":"10.1016\/j.htct.2022.06.003"},{"key":"400_CR82","unstructured":"Alfonso G, Arbelbide J, Basquiera AL, Belli C, Crisp R, Gonzalez J, et al. Gu\u00edas de diagn\u00f3stico y tratamiento. Neoplasias mielodispl\u00e1sicas y neoplasias mielodispl\u00e1sicas\/mieloproliferativas (2023). https:\/\/sah.org.ar\/docs\/guias\/2023\/Neoplasias_Mielodisplasicas_y_Neoplasias_Mielodisplasicas_Mieloproliferativas.pdf. Accessed Apr 17 2025."},{"key":"400_CR83","doi-asserted-by":"publisher","first-page":"4352","DOI":"10.1182\/blood-2022-166762","volume":"140","author":"VTM Hungria","year":"2022","unstructured":"Hungria VTM, Bittencourt R, Martinez G, Santos JDA, Almeida DRD, Figueiredo VLDP, et al. A Brazilian real-life experience of multiple myeloma patients: final results from the MMyBRAve multi-center study. Blood. 2022;140:4352\u20133. https:\/\/doi.org\/10.1182\/blood-2022-166762.","journal-title":"Blood"},{"issue":"Suppl 1","key":"400_CR84","doi-asserted-by":"publisher","first-page":"3327","DOI":"10.1182\/blood-2023-179050","volume":"142","author":"R Atallah","year":"2023","unstructured":"Atallah R, Shatnawi Y, Mammadzadeh A, Hashmi SK, Rana SK, Mushtaq MU, et al. The GLAMM1 study\u2014global access to myeloma medications: Potential barriers to chimeric antigen receptors (CART) and T-cell-engaging bispecific antibodies (TCE) globally. Blood. 2023;142(Suppl 1):3327\u20139. https:\/\/doi.org\/10.1182\/blood-2023-179050.","journal-title":"Blood"},{"issue":"7","key":"400_CR85","doi-asserted-by":"publisher","first-page":"6330","DOI":"10.3390\/curroncol30070467","volume":"30","author":"M Markouli","year":"2023","unstructured":"Markouli M, Ullah F, Unlu S, Omar N, Lopetegui-Lia N, Duco M, et al. Toxicity profile of chimeric antigen receptor T-cell and bispecific antibody therapies in multiple myeloma: pathogenesis, prevention and management. Curr Oncol. 2023;30(7):6330\u201352.","journal-title":"Curr Oncol"},{"key":"400_CR86","doi-asserted-by":"publisher","first-page":"7710","DOI":"10.1182\/blood-2022-163772","volume":"140","author":"ETT Gomez Gomez","year":"2022","unstructured":"Gomez Gomez ETT, Gomez Almaguer D, Gutierrez-Aguirre CH, Colunga-Pedraza PRR, Tarin-Arzaga L, Jaime JC, et al. Is VTD the best first line therapy for multiple myeloma in an environment with limited resources? An analysis of outcomes and costs. Blood. 2022;140:7710\u20131. https:\/\/doi.org\/10.1182\/blood-2022-163772.","journal-title":"Blood"},{"issue":"1","key":"400_CR87","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1007\/s00277-016-2866-9","volume":"96","author":"VT Hungria","year":"2017","unstructured":"Hungria VT, Maiolino A, Martinez G, Duarte GO, Bittencourt R, Peters L, et al. Observational study of multiple myeloma in Latin America. Ann Hematol. 2017;96(1):65\u201372. https:\/\/doi.org\/10.1007\/s00277-016-2866-9.","journal-title":"Ann Hematol"},{"issue":"9","key":"400_CR88","doi-asserted-by":"publisher","first-page":"1017","DOI":"10.1080\/17474086.2020.1800451","volume":"13","author":"AS Bruno","year":"2020","unstructured":"Bruno AS, Willson JL, Opalinska JM, Nelson JJ, Lunacsek OE, Stafkey-Mailey DR, et al. Recent real-world treatment patterns and outcomes in US patients with relapsed\/refractory multiple myeloma. Expert Rev Hematol. 2020;13(9):1017\u201325.","journal-title":"Expert Rev Hematol"},{"issue":"1","key":"400_CR89","doi-asserted-by":"publisher","first-page":"107327481983128","DOI":"10.1177\/1073274819831281","volume":"26","author":"LM Balderas-Pe\u00f1a","year":"2019","unstructured":"Balderas-Pe\u00f1a LM, Miranda-Ruvalcaba C, Robles-Espinoza AI, Sat-Mu\u00f1oz D, Ruiz MG, Garc\u00eda-Luna E, et al. Health-related quality of life and satisfaction with health care: relation to clinical stage in Mexican patients with multiple myeloma. Cancer Control. 2019;26(1):1073274819831281. https:\/\/doi.org\/10.1177\/1073274819831281.","journal-title":"Cancer Control"},{"key":"400_CR90","doi-asserted-by":"publisher","unstructured":"Andrade Neto JD, Fontes BPC, Macedo RD, Alessandro, Sim\u00f5es CE. Patients with spinal metastasis submitted to neurological decompression and stabilization. Coluna\/Columna. 2016;15(3):230\u20134. https:\/\/doi.org\/10.1590\/S1808-185120161503147903.","DOI":"10.1590\/S1808-185120161503147903"},{"issue":"3","key":"400_CR91","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1016\/j.hemonc.2017.05.027","volume":"10","author":"S Vigolo","year":"2017","unstructured":"Vigolo S, Zuckermann J, Bittencourt RI, Silla L, Pilger DA. Comparison of cyclophosphamide\u2013thalidomide\u2013dexamethasone to bortezomib\u2013cyclophosphamide\u2013dexamethasone as induction therapy for multiple myeloma patients in Brazil. Hematol Oncol Stem Cell Ther. 2017;10(3):135\u201342. https:\/\/doi.org\/10.1016\/j.hemonc.2017.05.027.","journal-title":"Hematol Oncol Stem Cell Ther"},{"key":"400_CR92","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2021.637593","volume":"12","author":"M Selvy","year":"2021","unstructured":"Selvy M, Kerckhove N, Pereira B, Barreau F, Nguyen D, Busserolles J, et al. Prevalence of chemotherapy-induced peripheral neuropathy in multiple myeloma patients and its impact on quality of life: a single center cross-sectional study. Front Pharmacol. 2021;12:637593.","journal-title":"Front Pharmacol"},{"issue":"3","key":"400_CR93","doi-asserted-by":"publisher","first-page":"356","DOI":"10.2174\/1574886318666230817162424","volume":"19","author":"PL de Miranda Drummond","year":"2024","unstructured":"de Miranda Drummond PL, dos Santos RMM, Silveira LP, Malta JS, Reis AMM, Costa NL, et al. Chemotherapy-induced peripheral neuropathy impacts quality of life and activities of daily living of Brazilian multiple myeloma patients. Curr Drug Saf. 2024;19(3):356\u201367. https:\/\/doi.org\/10.2174\/1574886318666230817162424.","journal-title":"Curr Drug Saf"},{"issue":"1","key":"400_CR94","doi-asserted-by":"publisher","first-page":"1167","DOI":"10.1080\/13696998.2022.2133823","volume":"25","author":"M Choon-Quinones","year":"2022","unstructured":"Choon-Quinones M, Zelei T, Barnett M, Keown P, Durie B, Kal\u00f3 Z, et al. Beyond medicines\u2019 barriers: exploring the true cost of multiple myeloma. J Med Econ. 2022;25(1):1167\u201375.","journal-title":"J Med Econ"},{"key":"400_CR95","doi-asserted-by":"publisher","DOI":"10.1016\/j.clml.2024.04.004","author":"C Bennink","year":"2024","unstructured":"Bennink C, Brink M, Duijts SF, Scheurer H, Sonneveld P, Blommestein HM. Changes in income and employment after diagnosis among patients with multiple myeloma in the Netherlands. Clin Lymphoma Myeloma Leuk. 2024. https:\/\/doi.org\/10.1016\/j.clml.2024.04.004.","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"400_CR96","doi-asserted-by":"publisher","DOI":"10.1016\/j.jbo.2019.100243","volume":"17","author":"S Kolovos","year":"2019","unstructured":"Kolovos S, Nador G, Kishore B, Streetly M, Rabin NK, Chantry AD, et al. Unplanned admissions for patients with myeloma in the UK: low frequency but high costs. J Bone Oncol. 2019;17:100243.","journal-title":"J Bone Oncol"},{"issue":"8","key":"400_CR97","first-page":"917","volume":"29","author":"J Yang","year":"2023","unstructured":"Yang J, Boytsov N, Carlson JJ, Barthold D. Health care resource utilization and costs among patients with multiple myeloma with exposure to double-class or triple-class multiple myeloma treatments: a retrospective US claims database analysis. J Manag Care Spec Pharm. 2023;29(8):917\u201326.","journal-title":"J Manag Care Spec Pharm"},{"issue":"15","key":"400_CR98","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2016.34.15_suppl.6621","volume":"34","author":"H Goldschmidt","year":"2016","unstructured":"Goldschmidt H, Vij R, Kuter D, Cella D, Zyczynski TM, Davis CC, et al. Health care resource utilization (HCRU) in relapsed\/refractory multiple myeloma (RRMM): results from preamble. J Clin Oncol. 2016;34(15):6621.","journal-title":"J Clin Oncol"},{"issue":"3","key":"400_CR99","doi-asserted-by":"publisher","first-page":"274","DOI":"10.5935\/2526-5393.20210043","volume":"5","author":"EAG Menezes","year":"2021","unstructured":"Menezes EAG, Ara\u00fajo GMB, Rabelo IA, Aarestrup BJV, Aarestrup PF, Cheloni EPC, et al. Avalia\u00e7\u00e3o do emprego da imunoglobulina humana endovenosa sobre a densidade de infec\u00e7\u00f5es em pacientes com mieloma m\u00faltiplo. Arq Asma Alerg Imunol. 2021;5(3):274\u20138. https:\/\/doi.org\/10.5935\/2526-5393.20210043.","journal-title":"Arq Asma Alerg Imunol"},{"issue":"5","key":"400_CR100","doi-asserted-by":"publisher","first-page":"1236","DOI":"10.1080\/10428194.2021.2012665","volume":"63","author":"L Bojalil-Alvarez","year":"2022","unstructured":"Bojalil-Alvarez L, Gertz MA, Garcia-Villase\u00f1or E, Fern\u00e1ndez-Guti\u00e9rrez JA, Reyes-Cisneros OA, Murrieta-Alvarez I, et al. Long term survival in multiple myeloma: a single institution experience in underprivileged circumstances. Leuk Lymphoma. 2022;63(5):1236\u201341. https:\/\/doi.org\/10.1080\/10428194.2021.2012665.","journal-title":"Leuk Lymphoma"},{"issue":"4","key":"400_CR101","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1016\/j.bjhh.2016.06.004","volume":"38","author":"EDQ Crusoe","year":"2016","unstructured":"Crusoe EDQ, Higashi F, Martinez GA, Barros JC, Bellesso M, Rossato M, et al. Is it feasible to use granulocyte-colony stimulating factor alone to mobilize progenitor cells in multiple myeloma patients induced with a cyclophosphamide, thalidomide and dexamethasone regimen? Rev Bras Hematol Hemoter. 2016;38(4):302\u20139. https:\/\/doi.org\/10.1016\/j.bjhh.2016.06.004.","journal-title":"Rev Bras Hematol Hemoter"},{"issue":"12","key":"400_CR102","doi-asserted-by":"publisher","first-page":"4996","DOI":"10.1007\/s12325-020-01521-9","volume":"37","author":"V Hungria","year":"2020","unstructured":"Hungria V, Mart\u00ednez-Ba\u00f1os DM, Mateos MV, Dimopoulos MA, Cavo M, Heeg B, et al. Daratumumab plus bortezomib, melphalan, and prednisone versus standard of care in Latin America for transplant-ineligible newly diagnosed multiple myeloma: propensity score matching analysis. Adv Ther. 2020;37(12):4996\u20135009. https:\/\/doi.org\/10.1007\/s12325-020-01521-9.","journal-title":"Adv Ther"},{"issue":"2","key":"400_CR103","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1007\/s00277-015-2537-2","volume":"95","author":"VT Hungria","year":"2016","unstructured":"Hungria VT, Cruso\u00e9 EQ, Maiolino A, Bittencourt R, Fantl D, Maciel JF, et al. Phase 3 trial of three thalidomide-containing regimens in patients with newly diagnosed multiple myeloma not transplant-eligible. Ann Hematol. 2016;95(2):271\u20138. https:\/\/doi.org\/10.1007\/s00277-015-2537-2.","journal-title":"Ann Hematol"},{"issue":"1","key":"400_CR104","first-page":"43","volume":"17","author":"K Mart\u00ednez","year":"2023","unstructured":"Mart\u00ednez K, Vallejos V, Sald\u00edas S, D\u00edaz M, Garrido B, Fuentes J. Defunciones por mieloma m\u00faltiple en Chile entre 2018\u20132022 por sexo, edad, temporalidad y regi\u00f3n nacional. Rev ANACEM (Impresa). 2023;17(1):43\u20137.","journal-title":"Rev ANACEM (Impresa)"},{"key":"400_CR105","doi-asserted-by":"publisher","unstructured":"Silva PVR, P\u00e1dua CAM, Machado TRL, Drummond PLM, Silveira LP, Malta JS, Reis AMM. Use of potentially inappropriate medications and medications of concern in older adults with multiple myeloma. Geriatr Gerontol Aging. 2024;18:e0000044-e. https:\/\/doi.org\/10.53886\/gga.e0000044_PT.","DOI":"10.53886\/gga.e0000044_PT"},{"key":"400_CR106","doi-asserted-by":"publisher","first-page":"4269","DOI":"10.1182\/blood-2022-163074","volume":"140","author":"N Puig","year":"2022","unstructured":"Puig N, Hungria VTM, Chari A, Davies FE, Cook G, H\u00e1jek R, et al. Global treatment standard in multiple myeloma remains elusive: updated results from the INSIGHT MM global, prospective, observational study. Blood. 2022;140:4269\u201372. https:\/\/doi.org\/10.1182\/blood-2022-163074.","journal-title":"Blood"},{"key":"400_CR107","doi-asserted-by":"publisher","unstructured":"Riva E, Schutz NP, Pe\u00f1a C, Villano F, Ruiz-Arg\u00fcelles GJ, Navarro JR, et al. Significant differences in test availability and access to novel drugs for multiple myeloma between public and private hospitals in Latin America. Grupo De Estudio Latinoamericano De Mieloma Multiple (GELAMM). Blood. 2018;132. https:\/\/doi.org\/10.1182\/blood-2018-99-111429.","DOI":"10.1182\/blood-2018-99-111429"},{"issue":"1","key":"400_CR108","first-page":"27","volume":"23","author":"M Pineli","year":"2018","unstructured":"Pineli M, Amigo C, Alvarado CA, Figueroa R, Bucheli E. Multiple myeloma: burden of disease analysis in some countries of Latin America. Oncol Clin. 2018;23(1):27\u201334.","journal-title":"Oncol Clin"},{"issue":"3","key":"400_CR109","doi-asserted-by":"publisher","first-page":"A77","DOI":"10.1016\/j.jval.2014.03.448","volume":"17","author":"V Vitale","year":"2014","unstructured":"Vitale V, Pinto Neto JV, Asano E. Total treatment costs analysis between subcutaneous and intravenous bortezomib under Brazilian private health care system perspective. Value Health. 2014;17(3):A77. https:\/\/doi.org\/10.1016\/j.jval.2014.03.448.","journal-title":"Value Health"},{"issue":"2","key":"400_CR110","doi-asserted-by":"publisher","first-page":"148","DOI":"10.21115\/JBES.v10.n2.p148-156","volume":"10","author":"CO Fioratti","year":"2018","unstructured":"Fioratti CO, Rosim RP, Scaccabarozzi L, Ribeiro GN. Custo-efetividade do esquema com daratumumabe, bortezomibe e dexametasona em compara\u00e7\u00e3o com terapias \u00e0 base de carfilzomibe, elotuzumabe e ixazomibe para o tratamento de mieloma m\u00faltiplo recidivado e refrat\u00e1rio na perspectiva de um pagador do sistema de sa\u00fade suplementar brasileiro. J Bras Econ Sa\u00fade. 2018;10(2):148\u201356. https:\/\/doi.org\/10.21115\/JBES.v10.n2.p148-156.","journal-title":"J Bras Econ Sa\u00fade"},{"key":"400_CR111","doi-asserted-by":"publisher","first-page":"S36","DOI":"10.1016\/j.jval.2018.09.212","volume":"21","author":"RP Rosim","year":"2018","unstructured":"Rosim RP, Julian G, Mendes A, Ricco M, Fioratti CO, Scaccabarozzi L. Treatment costs and progression-free survival of DVd and KRd regimens sequences in the Brazilian private healthcare system. Value Health. 2018;21:S36. https:\/\/doi.org\/10.1016\/j.jval.2018.09.212.","journal-title":"Value Health"},{"key":"400_CR112","doi-asserted-by":"publisher","first-page":"S479","DOI":"10.1016\/j.jval.2019.09.418","volume":"22","author":"S Tanaka","year":"2019","unstructured":"Tanaka S, Coggia A, Arancibia A, Majer IM, Aratangy G. PCN222 carfilzomib\/lenalidomide\/dexamethasone in the second-line setting followed by daratumumab\/lenalidomide\/dexamethasone in the third-line setting versus the opposite treatment sequence: a cost comparison study from a Brazilian private health care perspective. Value Health. 2019;22:S479. https:\/\/doi.org\/10.1016\/j.jval.2019.09.418.","journal-title":"Value Health"},{"issue":"3","key":"400_CR113","doi-asserted-by":"publisher","DOI":"10.5867\/medwave.2018.03.7220","volume":"18","author":"S Aceituno","year":"2018","unstructured":"Aceituno S, Gozalbo I, Appierto M, Liz\u00e1n L. Cost-effectiveness of lenalidomide in combination with dexamethasone compared to bortezomib in combination with dexamethasone for the second-line treatment of multiple myeloma in Chile. Medwave. 2018;18(3):e7220. https:\/\/doi.org\/10.5867\/medwave.2018.03.7220.","journal-title":"Medwave"},{"key":"400_CR114","unstructured":"Guevara C, Parody E, Merch\u00e1n \u00c1, Aguirre A: Report No. 179. An\u00e1lisis de costo-efectividad del esquema de quimioterapia bortezomib m\u00e1s ciclofosfamida m\u00e1s dexametasona versus bortezomib m\u00e1s talidomida m\u00e1s dexametasona versus lenalidomida m\u00e1s dexametasona como tratamiento de inducci\u00f3n en pacientes con mieloma m\u00faltiple activo y riesgo est\u00e1ndar en Colombia (2016). https:\/\/fi-admin.bvsalud.org\/document\/view\/g39qq. Accessed May 2 2025."},{"issue":"12","key":"400_CR115","doi-asserted-by":"publisher","first-page":"S187","DOI":"10.1016\/j.jval.2023.09.956","volume":"26","author":"R Romero","year":"2023","unstructured":"Romero R, Mena V. EE691 economic evaluation and budget impact of rvd as induction regimen prior to ASCT in patients with newly diagnosed multiple myeloma from the perspective of the public health sector in Mexico. Value Health. 2023;26(12):S187. https:\/\/doi.org\/10.1016\/j.jval.2023.09.956.","journal-title":"Value Health"}],"container-title":["Oncology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40487-025-00400-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40487-025-00400-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40487-025-00400-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,16]],"date-time":"2026-03-16T13:44:20Z","timestamp":1773668660000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40487-025-00400-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,26]]},"references-count":115,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,3]]}},"alternative-id":["400"],"URL":"https:\/\/doi.org\/10.1007\/s40487-025-00400-z","relation":{},"ISSN":["2366-1070","2366-1089"],"issn-type":[{"value":"2366-1070","type":"print"},{"value":"2366-1089","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,26]]},"assertion":[{"value":"5 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 October 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 November 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Guillermina Remaggi declares receiving honoraria as a speaker from Janssen, Sanofi and Pfizer; advisory board for Janssen, Sanofi, Pfizer and GSK. Roberto Jos\u00e9 Pessoa de Magalh\u00e3es declares receiving honoraria as a speaker and on advisory boards from Bristol Myers Squibb, GSK, Janssen, Pfizer and Sanofi. Cristian Maximiliano Seehaus, Jayr Schmidt Filho, Ricardo Bigni and Ruddy Dalfeor have no conflicts of interest to disclose. Paola Ochoa declares receiving honoraria as a speaker from Bristol Myers Squibb, GSK, Johnson and Johnson and Sanofi; advisory board for Bristol Myers Squibb, GSK, Johnson and Johnson, Pfizer and Sanofi; travel support from Johnson and Johnson and Sanofi. Bhumika Aggarwal and Jacopo Bitetti are employed by GSK and hold financial equities in GSK. Claudia Soares was an employee of GSK and held financial equities in GSK at the time of manuscript initiation.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"This article is based on previously conducted studies and does not contain any new studies with human participants or animals performed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}